The Latest Cardiac and Vascular News
Boston Scientific decides it’s too risky and that there are “bigger” problems to deal with. Boston Scientific to end Renuvia bioresorbable coronary stent program JULY 31, 2017 BY FINK DENSFORD, MassDevice Boston Scientific (NYSE:BSX) is looking to terminate its Renuvia bioresorbable coronary stent […]
By Ken Dropkiewski The bioresorbable stent was approved for use by the FDA in July of 2016. The Absorb GT1 Bioresorbable Vascular Scaffold System, manufactured by Abbott, was all set to solve a litany of the problems inherent with conventional […]
